Rivas EE

Language: Spanish
References: 16
Page: 1-3
PDF size: 130.42 Kb.

Text Extraction

No abstract.

REFERENCES

1. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020;382:1653-9

2. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426: 450-4.

3. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020(2); 181: 271-80.e8 Disponible en: https://doi.org/10.1016/j.cell.2020.02.052

4. Sommerstein R, Grani C. Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19. BMJ 2020; 368: m810

5. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens 2020 March 11 (Epub ahead of print).

6. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 2020 March 18 (Epub ahead of print).

7. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z et al. on behalf of the China Hypertension Survey Investigators. Status of hypertension in China: results from the China Hypertension Survey, 2012-2015. Circulation 2018; 137: 2344-56.

8. Campbell NRC, Zhang X-H. Hypertension in China. Time to Transition From Knowing the Problem to Implementing the Solution. Circulation. 2018;137:2357–9 https://doi.org/10.1161/CIRCULATIONAHA.118.034028

9. Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1・7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet 2017; 390: 2549-58.

10. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605-10.

11. Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) 2012; 123: 649-58. DOI: 10.1042/CS20120162

12. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 2004; 383: 45-51. DOI: 10.1042/bj20040634

13. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612-4. doi:10.1001/jama.2020.4326

14. NIH Panel Issues Guidelines for COVID-19 Treatment, April 22, 2020, https://covid19treatmentguidelines.nih.gov/ visitado: mayo 2, 2020.

15. American College of Cardiology. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. 2020. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. visitado: mayo 2, 2020.

16. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). A Review. JAMA. 2020;323(18):1824-36. doi:10.1001/jama.2020.6019. visitado: mayo 2, 2020.